Use of a sugar selected from lactose, fructose and raffinose, for increasing serpin expression in Bifidobacterium longum strain CNCM I-2618.

The present invention relates to a preparation method for various novel fucosyl oligosaccharides and a use thereof. More specifically, the present invention allows a preparation of various novel fucosyl oligosaccharides through an enzymatic reaction with α-1,2-fucosyltransferase using a GDP-L-fucose donor and various glucose acceptors and an establishment of probiotic characteristics thereof, and thus has an effect of providing uses as materials for medicines, food, cosmetic products, and the like.

The present invention relates to a preparation method for various novel fucosyl oligosaccharides and a use thereof. More specifically, the present invention allows a preparation of various novel fucosyl oligosaccharides through an enzymatic reaction with α-1,2-fucosyltransferase using a GDP-L-fucose donor and various glucose acceptors and an establishment of probiotic characteristics thereof, and thus has an effect of providing uses as materials for medicines, food, cosmetic products, and the like.

A pharmaceutical paste formulation containing an active ingredient, an API solubilizer, a cross-linking agent, a consistency improver, a rheology modifier, a humectant, and a liquid base.

A pharmaceutical paste formulation containing an active ingredient, an API solubilizer, a cross-linking agent, a consistency improver, a rheology modifier, a humectant, and a liquid base.

The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.

The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions comprise a means to sequester tears and an ophthalmological drug. The invention is further directed to methods of treating a spectrum of ocular surface disease epitheliopathies including but not limited to dry eye in a human or mammal. The invention is further directed to contact lenses, punctum plugs, pellets or any other device used to deliver drugs to the surface of the eye, coated or infused with compositions of the invention.

In an aspect of the present application, a composition for preventing or treating skin damage in skin of a mammalian subject in need thereof can include at least one autophagy promoter and at least one diuretic. The at least one autophagy promoter and the at least one diuretic, in combination, can each be present in an amount sufficient to prevent or treat the skin damage. In another aspect, the present application includes a method for preventing or treating skin damage in skin of a mammalian subject in need thereof whereby the composition can be administered to the subject in a therapeutically effective amount to prevent or treat the skin damage.

In an aspect of the present application, a composition for preventing or treating skin damage in skin of a mammalian subject in need thereof can include at least one autophagy promoter and at least one diuretic. The at least one autophagy promoter and the at least one diuretic, in combination, can each be present in an amount sufficient to prevent or treat the skin damage. In another aspect, the present application includes a method for preventing or treating skin damage in skin of a mammalian subject in need thereof whereby the composition can be administered to the subject in a therapeutically effective amount to prevent or treat the skin damage.

Methods of reducing oxidative damage to an eye of a subject are provided. Aspects of the method include intravitreal injection an antioxidant composition consisting essentially of a non-reducing sugar or a hydrate thereof. In some embodiments, the non-reducing sugar is trehalose. The methods can further include surgical removal of at least a portion of the subject's vitreous humor during a vitrectomy. Also provided are ophthalmic compositions, kits and pre-loaded injection devices for use in vitrectomy surgery which find use in the subject methods.